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Introduction: Mutation in the core promoter of the telomerase reverse transcriptase (TERT) gene was
determined to be a frequent event in malignant melanoma and other cancers. However, the role of TERT
promoter mutation in hepatocellular carcinomas (HCCs) remains largely unknown.
Methods: Genomic DNA samples from the tumor tissue of 195 HCCs were analyzed for TERT promoter
mutation at 2 hotspots (124 and 146 bp from the ATG start site, g.1,295,228 and g.1,295,250,
respectively) through direct sequencing.
Results: The TERT promoter mutation was identiﬁed in 57 of the 195 HCCs (29.2%) and was associated
with old age (P ¼ 0.0122), presence of anti-hepatitis C (HCV; P ¼ 0.0048), and absence of hepatitis B
surface antigen (HBsAg; P ¼ 0.0007). However, the TERT promoter mutation did not correlate with serum
a-fetoprotein levels, liver cirrhosis, tumor size, tumor grade, tumor stage, early tumor recurrence, b-
catenin mutation or p53 mutation. A multivariate analysis conﬁrmed that the absence of hepatitis B
infection is an independent factor associated with TERT promoter mutation. Furthermore, among HCC
patients infected with hepatitis C, those with concomitant hepatitis B infection exhibited infrequent
TERT promoter mutation (P ¼ 0.0435). Remarkably, patients presenting with TERT promoter mutation-
positive and -negative HCCs exhibited similar disease-free and overall survival rates.
Conclusions: Our study indicated that the TERT promoter mutation frequently occurred in HCV-
associated HCCs. The absence of Hepatitis B infection was signiﬁcantly associated with the TERT pro-
moter mutation. These ﬁndings suggest that various etiological factors may be involved in differing
mechanisms to preserve telomeres during the carcinogenesis of HCCs.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.n).
by Elsevier Ltd. All rights reserved1. Introduction
Hepatocellular carcinoma (HCC) is a common fatal malignancy
in Taiwan and several countries in Asia and Africa [1]. The major.
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cirrhosis of any etiology, and aﬂatoxin exposure [2]. Despite
improved treatment, most patients presenting with HCC die soon
after diagnosis because most cases are discovered at a late stage
and no effective systemic chemotherapy is available for unresect-
able tumors. Molecular approaches have indicated the involvement
of p53 and b-catenin mutations in hepatocarcinogenesis [3,4].
Mutations in several other genes have been recently identiﬁed
using exome sequencing [5e7]. However, the frequency of muta-
tions in these genes is considerably low and the molecular mech-
anisms of HCC remain ambiguous.
Telomeres are repetitive DNA sequences at the ends of chro-
mosomes that preserve genome integrity and stability [8]. Telo-
meres shorten after repeated cell division. Telomere shortening
causes genome instability because it induces chromosome end
resection, fusion, and breakage [8]. Maintaining telomeres is
essential for tumor formation. Two mechanisms of telomere
maintenance were identiﬁed in tumor cells: the activation of
telomerase and alternative mechanisms of telomere lengthening
[8]. Telomerase activation is the principal mechanism for the
maintaining telomere length in HCCs [9]. Telomerase is a ribonu-
cleoprotein complex that adds repetitive DNA sequences to the
telomeres. In normal adult tissue, telomerase activity occurs in only
limited cell types, including germ cells, bone marrow stem cells,
and basal cells of certain epithelia [10,11]. Telomerase activation in
human tumors plays a key role in cellular immortalization [12].
Active telomerase has been detected in more than 80% of HCC tu-
mor specimens [13,14]. The mechanisms for telomerase activation
in HCCs include activation by hepatitis B virus (HBV) X protein
(HBx) [15], integrating the HBV genome into the human telomerase
reverse transcriptase (TERT) gene promoter [16], and the regulating
TERT expression by cellular oncogenes [17].
Recently, 2 independent mutations in the core TERT promoter
were identiﬁed in familial and sporadic melanomas [18,19]. The
mutation frequency is as high as 71% in malignant melanomas [18].
Both mutations generated novel binding sites for E-twenty-six
transcription factors, and the mutations increased transcriptional
activity of the TERT promoter from 2- to 4-fold [18]. A subsequent
study determined that the TERT promoter was frequently mutated
in various cancers, and HCC tumors exhibited the highest frequency
of TERT promoter mutation [20,21].
In this study, we used direct sequencing to determine the fre-
quency of TERT promoter mutation in a large cohort of HCCs in
Taiwan, analyzing the correlation between TERT promoter muta-
tion and clinicopathological and molecular factors.
2. Materials and methods
2.1. Tissue sample
A total of 195 primary HCC tumors resected from patients at the
National Taiwan University Hospital from January 1983 to August
1997 were used in this study. All resected tumors underwent
detailed pathological assessment, and all patients received regular
follow-up examinations, as described previously [22,23]. This study
was approved by the Ethics Committee of National Taiwan Uni-
versity Hospital (NTUH-REC No.: 201305015RINB, date of approval:
August 6, 2013), and all study procedures were conducted based on
ethical guidelines. All study participants provided their written
informed consent, which was approved by the Ethics Committee of
the National Taiwan University Hospital. One teenaged male was
included in our study, for whom written informed consent was
obtained from his parents; no other minors were included. The
anonymity of each patient was maintained, and all specimens were
blindly analyzed. The patients comprised 158 men and 37 women,exhibiting amean age of 56.6 years (range 8e93 y). All tumors were
resectable. Serum hepatitis B surface antigen (HBsAg) was detected
in 121 patients, anti-HCV antibody was detected in 70 patients, and
20 patients were positive for both. None of the patients received
transhepatic arterial embolization or chemotherapy before surgery.
After discharged from hospital, all patients received examinations
including serum a-fetoprotein (AFP) at 1- to 6-month intervals and
ultrasonography of the liver at 3- to 12-month intervals. Patients
who failed to return to the clinic as scheduled were contacted by
telephone. In the event of death, the date and the cause of death
were recorded.
2.2. Histology and tumor staging
The resected specimens were formalin-ﬁxed and parafﬁn-
embedded. Histological sections were cut at 5-mm thickness and
stained with hematoxylin-eosin. All specimens were reviewed by
the same investigator (JYM) to determine tumor grade and stage.
The tumor grade was based on the criteria proposed by Edmonson
and Steiner [24]. The tumors were staged according to the system of
the American Joint Committee on Cancer [25]. Because the study
evaluated the prognostic value of resectable HCCs, patients classi-
ﬁed with stages IVA and IVB were excluded. The margins of the
surgical specimens were inked and assessed microscopically. Only
completely resected specimens exhibiting negative margins were
included in this study.
2.3. Analysis of TERT promoter mutation
The tissue samples were immediately cut into small pieces,
snap-frozen in liquid nitrogen, and stored in deep freezers.
Genomic DNA was extracted using the phenol/chloroform method.
The samples were subjected to a polymerase chain reaction (PCR)
by using pairs of primers encompassing the mutational hotspots in
the TERT promoter: TERT-F: 50-GGGGCCAGGGCTTCCCACGTG-30
and TERT-R: 50-CACCTTCCAGCTCCGCCTCCTC-30. The PCR was per-
formed in an automatic DNA thermal cycler (PerkinElmer, Well-
esley, MA, USA) at initial temperature of 95 C for 2 min, followed
by 30 cycles at 95 C for 30 s, 68 C for 30 s, 72 C for 30 s, and
ﬁnally, 72 C for 10 min. After puriﬁcation, direct sequencing was
performed using the primer TERT-se-F: 50-CAGCAGGACG-
CAGCGCTGCCTG-30 and TERT-se-R: 50-CAGCTCCGCCTCCTCCGCGC-
30 in an automated ABI 3730 sequencer (Applied BioSystems, Foster
City, CA, USA).
2.4. Analysis of p53 and b-catenin mutations
The p53 tumor suppressor gene mutations were analyzed in 117
tumors by directly sequencing the chromosomal region spanning
exon 2 to exon 11, as previously described [4]. The b-catenin gene
mutationswere analyzed in 131 cases by directly sequencing exon 3
in the chromosomal DNA, as previously described [3].
2.5. Real-time polymerase chain reaction
The SYBR green-based real-time PCR was performed to deter-
mine the levels of TERT mRNA by using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a
housekeeping gene, served as the control for RNA quantity. The
primers for TERT were TERT-F (50-AGCCAGAACGTTCCGCAGAG-30)
and TERT-R (50-CGTAGTTGAGCACGCTGAAC-30). The primers used
for GAPDH were GAPDH-F (50-AGCCTCAAGATCATCAGCAATGCC-30)
and GAPDH-R (50-TGTGGTCATGAGTCCTTCCACGAT-30). In a volume
of 20 mL PCR reaction, 1 mL of complementary DNA template was
Table 1
Univariate analysis of TERT promoter mutation with various clinicopathological
features and aberrant gene mutation in 195 patients with surgically removed pri-
mary hepatocellular carcinoma.
Variables TERT promoter mutation Odds ratio (95% CI) P value
Negative
(n ¼ 138)
Positive
(n ¼ 57)
Age
>56 75 (54) 42 (74) 0.43 (0.20e0.88) 0.0122
56 63 (46) 15 (26)
Gender
Male 111 (80) 47 (82) 0.87 (0.36e2.07) 0.7433
Female 27 (20) 10 (18)
HBsAg
Negative 40 (29) 31 (55) 0.34 (0.17e0.67) 0.0007
Positive 96 (71) 25 (45)
Anti-HCV
Negative 84 (66) 20 (43) 2.64 (1.26e5.55) 0.0048
Positive 43 (34) 27 (57)
a-fetoprotein (ng/ml)
 200 74 (54) 28 (50) 1.16 (0.87e1.25) 0.6470
>200 64 (46) 28 (50)
Cirrhosis
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Biosystems), 200 nM of paired primers, and distilled water. The PCR
ampliﬁcation included an initial incubation at 50 C for 2 min,
denaturing at 95 C for 10 min, 40 cycles of denaturing at 95 C for
15 s, and annealing at 60 C for 1 min. The melting curves were
analyzed after each run to verify the size of PCR product.
DCt ¼ CtLin-41CtGAPDH.
2.6. Statistical analysis
The analyses were conducted using StatCalc for Windows soft-
ware (Epi Info™ Version 3.3.2, Centers for Disease Control and
Prevention, Atlanta, GA, USA). The c2 and Fisher0s exact tests were
used for univariate analysis. The survival rates were calculated
using the KaplaneMeier method, and the difference in survival
curves was analyzed using the log-rank test. A multivariate analysis
on all the parameters that were analyzed in univariate analysis was
performed by the Logistic regression model to detect the factors
correlated with the TERT promoter mutation. The two-tailed P
values of <0.05 were statistically signiﬁcant.
3. Results
3.1. Mutation of the telomerase reverse transcriptase promoter in
hepatocellular carcinoma
The primers were designed to amplify the region containing two
TERT promoter mutations that were previously described, C228T
and C250T, corresponding to the positions 124 bp and 146 bp,
respectively, upstream of the TERT ATG start site. [18e20] Direct
sequencing indicated TERT promoter mutation in 57 of 195 HCCs
(29.2%). Fifty-four (94.7%) mutations were C228T, whereas 3 (5.3%)
mutations were C250T (Fig. 1). The C250T and C228T mutations
were mutually exclusive. The nontumorous parts of selected cases
were also analyzed, and none exhibited mutations, indicating that
the mutations were somatic. No other genetic variants were
detected in the analyzed regions.
3.2. Clinical and pathological signiﬁcance of telomerase reverse
transcriptase promoter mutation in hepatocellular carcinoma
To elucidate the importance of TERT promoter mutation in HCC,
we examined possible correlations between TERT promoter mu-
tation and the major clinicopathological and molecular factors of
HCCs. As shown in Table 1, TERT promoter mutations were corre-
lated with aged patients (P ¼ 0.0122). On average, patients pre-
senting with TERT promoter mutation-positive HCC were 6 yearsFig. 1. TERT promoter mutation in HCC. Sequence chromatograms of matched DNA
from HCC (A, B) and nontumorous liver parenchyma (C, D) demonstrated somatic
mutations in chromosome 5 [1,295,228C > T (C228T)] and chromosome 5
[1,295,250C > T (C250T)] in the TERT promoter locus.older than those with TERT promoter mutation-negative HCC (61.1
vs. 54.7 y). In addition, TERT promoter mutationwas detected in 25
of 121 (20.7%) HCCs of HBsAg-positive patients and in 31 of 71
(43.6%) HCCs from HBsAg-negative patients (P ¼ 0.0007). By
contrast, TERT promoter mutationwas more frequently detected in
HCCs of anti-HCV-positive patients compared with anti-HCV-
negative patients (38.5% vs. 19.2%, P ¼ 0.0048). The multivariate
analysis (Table 2) using all the parameters used in univariate
analysis conﬁrmed that absence of hepatitis B infection was an
independent factor associated with TERT promoter mutation
(P ¼ 0.0087). However, age and hepatitis C infection were not
independently associated with TERT promoter mutations. TERT
promoter mutation did not correlate with other factors such as
gender, serum AFP levels, liver cirrhosis, tumor size, tumor grade,
tumor stage, or early tumor recurrence. The KaplaneMeier survival
analysis indicated that patients presenting with TERT promoter
mutation-positive and -negative HCCs exhibited similar 5-year
disease-free and 5-year overall survival rates (Fig. 2A and B).
We analyzed the survival of patients stratiﬁed according to the
tumor stage at presentation and the presence or absence of hepa-
titis B or C infection with status of TERT promoter mutation. As
shown in Fig. 3A, patients who presented with high-stage tumor
exhibited the lowest 5-years survival rates, whereas those pre-
sented with low-stage tumor exhibited the highest rates
(P < 0.0001). Regarding patients who presented with tumors at the
same stage, the 5-yers survival rates were similar regardless of theNo 82 (59) 30 (53) 1.32 (0.68e2.57) 0.3832
Yes 56 (41) 27 (47)
Tumor size (cm)
<5 57 (41) 26 (46) 0.84 (0.43e1.64) 0.5799
5 81 (59) 31 (54)
Tumor grade
1 32 (23) 17 (30) 0.71 (0.34e1.50) 0.3312
2e4 106 (77) 40 (70)
Tumor stage
I 63 (46) 26 (46) 1.00 (0.51e1.95) 0.9961
II ~ III 75 (54) 31 (54)
Early tumor recurrence
No 50 (46) 25 (58) 0.62 (0.29e1.34) 0.1890
Yes 58 (54) 18 (42)
p53 mutation
No 65 (52) 34 (68) 0.52 (0.24e1.09) 0.0603
Yes 59 (48) 16 (32)
b-catenin mutation
No 114 (86) 43 (78) 1.67 (0.70e4.00) 0.2055
Yes 19 (14) 12 (22)
Table 2
Multivariate analysis of clinicopathological and molecular factors associated with TERT promoter mutation in 195 patients with surgically removed primary hepatocellular
carcinoma.
Covariate Coefﬁcient S.E. Z-Statistic O.R. (95% C.I.) P value
Age 0.1837 0.4986 0.3685 0.8322 (0.3132e2.2112) 0.7125
Sex (M/F) 1.0076 0.6635 1.5187 2.7391 (0.7462e10.0544) 0.1288
HBsAg (P/N) 1.6310 0.6097 2.6754 0.1957 (0.0593e0.6465) 0.0075
Anti-HCV (P/N) 0.3538 0.5591 0.6328 1.4245 (0.4762e4.2613) 0.5268
AFP (L/H) 0.0769 0.4958 0.1551 1.0799 (0.4087e2.8538) 0.8768
Size (S/L) 0.2518 0.5020 0.5015 1.2863 (0.4809e3.4410) 0.6160
Cirrhosis (P/N) 0.4202 0.4701 0.8939 1.5223 (0.6059e3.8248) 0.3714
Grade (L/H) 0.2608 0.2825 0.9231 0.7705 (0.4429e1.3403) 0.3559
Stage (L/H) 0.1996 0.3339 0.5978 1.2209 (0.6345e2.3493) 0.5500
ETRa (P/N) 0.0567 0.5286 0.1072 0.9449 (0.3353e2.6629) 0.9147
p53 mutation (P/N) 0.3397 0.4822 0.7046 0.7120 (0.2767e1.8317) 0.4810
b-catenin mutation (P/N) 0.0142 0.6180 0.0231 0.9859 (0.2936e3.3104) 0.9816
Abbreviations: S.E., Standard error; O.R., Odds ratio; C.I., Conﬁdence interval; AFP, a-fetoprotein; ETR, early tumor recurrent; L, low or large; H, high; S, small; P, positive or
presence; N, negative or absence.
a Tumor recurrence within 12 months after hepatectomy.
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shown in Fig. 3B, patients not diagnosed with hepatitis B infection
exhibited a trend toward a high 5-years survival rate, regardless of
the presence of absence of TERT promotermutation (P¼ 0.0617). As
shown in Fig. 3C, patients presenting with concomitant hepatitis C
infection and TRET promoter mutation exhibited a trend toward a
high 5-years survival rate (P¼ 0.0534). However, the differencewas
insigniﬁcant compared with patients who presented with hepatitis
C infection but not TERT promoter mutation (P ¼ 0.1079).
The p53 and b-catenin genes are the most frequently mutated
genes in HCC [3,4]. In the HCC series of this study, p53 mutationwas
detected in 75 of 174 cases (43.1%), and b-catenin mutation was
identiﬁed in 31 of 188 cases (16.5%). Thus, we analyzed the rela-
tionship between TERT promoter mutation and p53 and b-catenin
mutations, determining that TERT promoter mutation did not
correlate with b-cateninmutation. TERT promoter mutation tended
to occur in HCCs that lacked p53 mutation, exhibiting borderline
statistical signiﬁcance (P ¼ 0.0603).3.3. Correlation of hepatitis B infection and hepatitis C infection in
relation to molecular factors in hepatocellular carcinoma patients
To further substantiate the importance of hepatitis infection in
relation to the molecular factors of HCC, we performed a combi-
nation analysis. We divided the cases into 4 groups according to theFig. 2. Cumulative overall (A) and disease-free (B) 5-years survival curves for 195 patients w
TERT promoter mutation-positive HCC had similar overall and disease-free 5-years survivapresence or absence of hepatitis B infection and hepatitis C infec-
tion: HBsAg()/Anti-HCV(), HBsAg()/Anti-HCV(þ), HBsAg(þ)/
Anti-HCV(), and HBsAg(þ)/Anti-HCV(þ). As shown in Table 3,
TERT promoter mutation is closely related to the hepatitis infection
status (P¼ 0.0011). HCCs in patients with hepatitis C infection alone
were more likely to have TERT promoter mutation than those pa-
tients with hepatitis B infection alone (P ¼ 0.0001). Furthermore,
among the 2 groups of HCCs of hepatitis C patients, HCCs without
concomitant hepatitis B infection exhibited frequent TERT pro-
moter mutation (46% vs. 20%, P ¼ 0.0435). However, hepatitis
infection status did not correlate with p53 mutation or b-catenin
mutation.3.4. Telomerase reverse transcriptase mRNA expression in
hepatocellular carcinoma and nontumorous liver parenchyma
We analyzed the expression of TERT mRNA in 16 HCCs exhib-
iting TERT promoter mutation, 32 HCCs that did not exhibit TERT
promoter mutation, and 24 samples of nontumorous liver paren-
chyma by using real-time PCR. As shown in Fig. 4, TERT mRNA
expression was signiﬁcantly higher in both TERT promoter
mutation-positive and TERT promoter mutation-negative HCCs
than in the nontumorous liver parenchyma (P < 1  107 and
P < 1  105, respectively). However, the TERT promoter mutationith resected, primary HCC stratiﬁed by TERT promoter mutation status. Patients with
l to those with TERT promoter mutation-negative HCC.
Fig. 3. Cumulative overall 5-years survival for 195 patients with resected, primary HCC stratiﬁed according to the tumor stage at presentation, the presence or absence of hepatitis B
or C infection with status of TERT promoter mutation. Patients who presented with high-stage tumor exhibited the lowest 5-years survival rates, whereas those presented with low-
stage tumor exhibited the highest rates (P < 0.0001). Regarding patients who presented tumors in the same stage, the 5-years survival rates were similar regardless of the presence
of absence of TERT promoter mutation (3A; all Ps > 0.05). Patients not diagnosed with hepatitis B infection exhibited a trend toward a high 5-years survival rate, regardless of the
presence of absence of TERT promoter mutation (3B; P ¼ 0.0617). Patients presenting with concomitant hepatitis C infection and TRET promoter mutation exhibited a trend toward
a high 5-years survival rate (3C; P ¼ 0.0534). However, the difference was nonsigniﬁcant compared with patients who presented with hepatitis C infection but not TERT promoter
mutation (P ¼ 0.1079).
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(P > 0.05).
4. Discussion
In this Taiwanese cohort study, we analyzed the mutation status
of the TERT promoter in 195 HCCs, determining a mutation fre-
quency of 29.2%. This ﬁnding suggests that TERT promoter muta-
tion is the second most common genetic change in HCCs, after p53
mutation. Consistent with the results of Nault et al., we determined
that TRET promoter mutation correlates with the presence of
hepatitis C infection and is strongly associated with the absence of
HBV infection [21]. In addition, we disclosed, for the ﬁrst time, that
the absence of hepatitis B infection is an independent factor of TRET
promoter mutation. Furthermore, based on a combination analysis,
we determined that the frequency of TERT promoter mutation in
patients infected with hepatitis B alone and in patients concomi-
tantly infected with hepatitis B and hepatitis C was signiﬁcantly
lower than that in patients infected with hepatitis C alone. The
most likely explanation is that HBV-associated HCCs involve other
mechanisms of maintaining telomere integrity regardless of the
presence or absence of hepatitis C infection. It has been reported
that the TERT promoter is one of the most frequent integration sites
for the HBV genome in HCCs [11,26e29]. Inserting a viral genomecaused the juxtaposition of viral enhancers to be near the TERT
gene and the potential activation of TERT expression [29]. HBx
protein was reported to stimulate the TERT promoter through Sp1
binding sites mapped at 132 toþ5 nt in the hTERT promoter [10].
The HBV core protein was also reported to enhance TERT promoter
activity, depending on the binding of c-Ets2 to the promoter re-
gion between 192 and 187 [30]. These mechanisms may miti-
gate the need for TERT promoter mutation to activate TERT
transcription.
Killela et al. reported that 27 of the 61 HCCs (44.2%) harbor TERT
promoter mutation [20], and Nault et al. demonstrated that TERT
promoter mutation was detected in 179 of the 305 HCCs (58.7%)
[21]. These ﬁndings suggest that TERT promoter mutations are the
most frequent somatic genetic alternation in human HCCs. How-
ever, in this study, TERT promoter mutation occurred only in 57 of
the 195 HCCs (29.2%). HBV infection is the most frequent etiological
factor for HCCs in Taiwan and other Southeastern Asia countries,
whereas HCV infection is the most common cause of HCCs in
Western countries [31,32]. In this study, we determined that the
percentage of patients harboring HBsAg was signiﬁcantly higher
than in previous reports (62.1% vs. 22.1% and 62.1% vs. 24.6%;
P < 1  105 and P < 1  106, respectively) [20,21]. Thus, the dif-
ference in HBV prevalence may account for the varying TERT pro-
moter mutation rates.
Table 3
Combination of Hepatitis B infection and Hepatitis C infection status in relation to
molecular factors in patients with resected primary hepatocellular carcinoma.
Factors HBsAg/Anti-HCV P value
/ /þ /þ þ/þ
TERT promoter mutation
Presence 6 (40%) 23 (46%)a 14 (16%)a 4 (20%) 0.0011
Absence 9 (60%) 27 (54%)b 73 (84%) 16 (80%)b
p53 mutation
Presence 4 (29%) 19 (42%)c 33 (41%)c 10 (63%) 0.2861
Absence 10 (71%) 26 (58%)d 47 (59%) 6 (37%)d
b-catenin mutation
Presence 2 (13%) 14 (28%)e 11 (13%)e 1 (5%) 0.0631
Absence 13 (87%) 36 (72%)f 73 (87%) 18 (95%)f
a, b, c, d, e and f designate comparison between the indicated two groups.
P values: a0.0001; b0.0435; c0.9157; d0.1665; e0.0558; f0.0857.
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among aged patients. Chronic HBV infection is typically caused by
vertical transmission, and patients are infected during infancy.
Thus, the average age of HBV-related HCC patients is lower than
that in HCV-related HCC patients [33]. As mentioned, in this study,
a high percentage of patients harbored hepatitis B infection. This
may be the reason why patients with TERT promoter mutation-
positive HCCs were older than those with TERT promoter
mutation-negative HCCs. However, the results of this study did not
indicate correlations between TERT promoter mutationwith males,
low serum AFP levels, small tumors, and b-catenin mutation [21].
The reasons for these discrepancies are unclear andmight be due to
racial or ethnic differences among the patients, different etiology
and disease course in HBV-endemic and non-endemic areas.
The frequency of TERT promoter mutation was similar in low-
stage and high-stage HCCs, and TERT promoter mutation did not
affect patient survival rates, regardless of the presence or absence
of hepatitis B or hepatitis C infection. The most likely explanation is
that TERT promoter mutation occurs early in HCC disease. In this
study, 26 of the 89 stage I HCCs (29.2%) harbored TERT promoter
mutations. Consistent with our ﬁndings, Killela et al. observed that
TERT promoter mutation occurred in 39% of stage I well-Fig. 4. Quantiﬁcation of TERT mRNA expression in HCC and nontumorous liver pa-
renchyma by real time PCR. TERT mRNA expression was signiﬁcantly higher in both
TERT promoter mutation-positive and TERT promoter mutation-negative HCCs than in
nontumorous liver parenchyma (P < 1 107 and P < 1 105, respectively). However,
TERT promoter mutation status did not affect the TERT mRNA expression level in HCC.differentiated HCCs [20], and Tahara et al. determined that telo-
merase was expressed in 15 of 18 differentiated HCC nodules
smaller than 3 cm [13], indicating that telomerase activation is an
early step in liver carcinogenesis. TERT transcripts were detected at
high frequencies in cirrhotic livers, large regenerative nodules, and
dysplastic nodules, but were absent in normal livers [34]. Nault
et al. demonstrated that TERT promoter mutationwas the ﬁrst gene
to recurrently mutate in cirrhotic preneoplastic lesions, and was
involved at the ﬁnal step of malignant transformation of hepato-
cellular adenoma [21]. Although liver cirrhosis occurred in about
half of the patients with TERT promoter mutation, we failed to
show any signiﬁcant correlation of liver cirrhosis with TERT pro-
motermutation. Overall, these ﬁndings suggest that TERT promoter
mutation is an early event in hepatocarcinogenesis. Even though
we determined higher TERT mRNA expression in the HCC tumor
region than the nontumorous liver parenchyma, we did not
demonstrate any signiﬁcant difference in TERT mRNA expression
between TERT promoter mutation-positive and -negative HCCs. As
preserving telomere is essential for tumor cells, tumors that lack
TERT promoter mutation may have other mechanisms for acti-
vating TERT expression.
In conclusion, we determined the mutation rate of TERT pro-
moter to be approximately 30% in Taiwan, an HBV-endemic coun-
try. The mutation rates were similar for low-stage and high-stage
tumors. We determined that TERT promoter mutation was
frequently identiﬁed in HCV-associated HCCs. The absence of
hepatitis B infection was an independent factor associated with
TERT promoter mutation. The results indicated that distinct etio-
logical factors may involve various mechanisms of preserving
telomeres during carcinogenesis of HCCs.
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